Saturday, 27 February 2021

Biocon Biologics inducts Professor Peter Piot as Independent Director

21 January 2021 | News

Professor Piot has been appointed to the board of Biocon Biologics Limited for a period of three years starting January 21, 2021

Biocon Biologics announced that it has inducted Professor Peter Piot to its Board as an Independent Director. Professor Piot is the Director of the London School of Hygiene & Tropical Medicine and the Handa Professor of Global Health.

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said, “I welcome Professor Peter Piot to the Biocon Biologics board. His thought leadership and invaluable experience in global healthcare will greatly guide our actions in building Biocon Biologics into an innovative global leader in biosimilars committed to delivering affordable access to life saving Biologics.”

On his decision to join the Biocon Biologics board, Professor Peter Piot said: “I am delighted to join dynamic Biocon Biologics and its vital mission of bringing the products of innovation to those who can benefit from them. With several exciting biosimilar molecules in its pipeline, I believe Biocon Biologics has the potential to be truly disruptive in addressing a global need for high quality, affordable biosimilar therapies to treat chronic diseases like diabetes and cancer and save many lives.”

Professor Piot has been appointed to the board of Biocon Biologics Limited for a period of three years starting January 21, 2021.

Professor Peter Piot was initially trained in infectious diseases and medical microbiology, with original contributions in epidemiology, bacteriology, virology, and public health policy interventions mostly in low- and middle-income countries.

Professor Piot was part of the team that isolated the Ebola virus in Zaire in 1976. He also led pioneering research on HIV/AIDS, women’s health and infectious diseases, mostly in Africa. He was the founding Executive Director of UNAIDS and Under Secretary-General of the United Nations from 1995 until 2008.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account






Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls